SHARDACROP - Sharda Cropchem Limited Share Price

The management of Sharda Cropchem Limited provided an optimistic outlook during the Q3 FY 2025-26 earnings call. They expressed confidence in continuing growth momentum, emphasizing that Q4 FY 2026 is expected to be strong and that this growth would persist through FY 2027. The Chairman and Managing Director, R.V. Bubna, highlighted robust performance with a 39% revenue growth year-on-year to INR 1,289 crores, noting volume expansion of 14% and a significant increase in PAT by 366% to INR 145 crores.

Key forward-looking points include:

1. Growth Expectations: Management anticipates a volume growth of approximately 15% in FY 2027 and projected total revenue growth between 15% to 20% for FY 2027.

2. Margin Guidance: The company expects gross margins to stabilize around 35% for FY 2026 and potentially improve in FY 2027. EBITDA margins are projected to remain healthy in the 18%-20% range.

3. Product Registration Pipeline: As of December 31, 2025, Sharda holds 3,004 product registrations, with an additional 1,076 applications in the approval stage. The strong focus on securing registrations is seen as pivotal for market presence and sustainable growth.

4. Capital Expenditure: The planned capex for FY 2026 stands at INR 500 crores, potentially increasing to INR 450-500 crores in FY 2027 as they continue to invest in product registrations.

5. Financial Position: The company remains net debt-free with cash and bank liquid investments totaling INR 826 crores, reflecting a strong balance sheet that supports ongoing and future growth initiatives.

Overall, management conveyed a strong commitment to sustaining growth and improving profitability while effectively managing operational challenges.

Here's a summary of the Q&A section from the earnings call transcript dated January 30, 2026:

Question from Ansh Shah: "Can you give an idea about typical approval timelines for the 1,070 product registrations, particularly in Europe?"

Answer: "The registration process is highly uncertain. It can take anywhere from 1 to 7 years depending on regulatory changes. Unfortunately, I cannot provide a specific timeline as the process is unpredictable."

Question from Giriraj Daga: "Are we expecting a 15% volume growth in FY '27, and will the 35% gross margin sustain?"

Answer: "Yes, we are confident we can achieve a 15% volume growth. The 35% gross margin is sustainable, and it could potentially increase further in FY '27."

Question from Anubhav Mukherjee: "Can you break down the 38.7% growth in agrochemicals into its components regarding price and forex?"

Answer: "The growth consists of 14.4% from volume, 12.6% from forex, and 11.6% from price and product mix, totaling 38.7%."

Question from Dhruv Muchhal: "Is the growth in Europe driven by new dealers or expanding geography?"

Answer: "It's a combination of both"”adding new dealers and expanding our geographical reach. Both factors contribute to our growth in Europe."

Question from Sonal Minhas: "What actions have you taken to reduce working capital days from 98 to 70?"

Answer: "Our improved demand and supplier relationships have resulted in extended credit and timely payments from customers, contributing to reduced working capital days."

Question from Ankur Kumar: "Do you expect similar growth in Q4 as previous quarters with pricing improvements?"

Answer: "Yes, we anticipate similar growth in Q4, both in volume and pricing."

Question from Vignesh Iyer: "Can you provide gross margins by geography for Q3 FY '26?"

Answer: "Gross margins were 43% in Europe, 23.5% in NAFTA, 29.2% in LATAM, and 37% in the rest of the world, averaging out to 35.9% overall."

Question from Sachin Kasera: "With a strong cash position, are you considering increasing dividends?"

Answer: "Yes, we're exploring increasing dividends. Acquisitions are not on our agenda right now, but we have declared a solid dividend for this quarter."

This summary consolidates the key questions and answers provided in the Q&A segment of the earnings call while retaining critical details about timelines, expectations, and metrics.